Jacobson Kenneth A, Gao Zhan-Guo, Göblyös Anikó, Ijzerman Adriaan P
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Adv Pharmacol. 2011;61:187-220. doi: 10.1016/B978-0-12-385526-8.00007-2.
Among the purine and pyrimidine receptors, the discovery of small molecular allosteric modulators has been most highly advanced for the A(1) and A(3) adenosine receptors (ARs). These AR modulators have allosteric effects that are structurally separated from the orthosteric effects in SAR studies. The benzoylthiophene derivatives tend to act as allosteric agonists as well as selective positive allosteric modulators (PAMs) of the A(1) AR. A 2-amino-3-aroylthiophene derivative T-62 has been under development as a PAM of the A(1) AR for the treatment of chronic pain. Several structurally distinct classes of allosteric modulators of the human A(3) AR have been reported: 3-(2-pyridinyl)isoquinolines, 2,4-disubstituted quinolines, 1H-imidazo-[4,5-c]quinolin-4-amines, endocannabinoid 2-arachidonylglycerol, and the food dye Brilliant Black BN. Site-directed mutagenesis of A(1) and A(3) ARs has identified residues associated with the allosteric effect, distinct from those that affect orthosteric binding. A few small molecular allosteric modulators have been reported for several of the P2X ligand-gated ion channels and the G protein-coupled P2Y receptor nucleotides. Metal ion modulation of the P2X receptors has been extensively explored. The allosteric approach to modulation of purine and pyrimidine receptors looks promising for development of drugs that are event and site specific in action.
在嘌呤和嘧啶受体中,A(1)和A(3)腺苷受体(ARs)的小分子变构调节剂的发现最为先进。这些AR调节剂具有变构效应,在构效关系(SAR)研究中,其结构与正构效应是分开的。苯甲酰噻吩衍生物倾向于作为A(1) AR的变构激动剂以及选择性正变构调节剂(PAMs)起作用。一种2-氨基-3-芳酰基噻吩衍生物T-62已在开发中作为A(1) AR的PAM用于治疗慢性疼痛。已经报道了几种结构不同类别的人A(3) AR变构调节剂:3-(2-吡啶基)异喹啉、2,4-二取代喹啉、1H-咪唑并-[4,5-c]喹啉-4-胺、内源性大麻素2-花生四烯酸甘油酯以及食用染料亮黑BN。A(1)和A(3) AR的定点诱变已经确定了与变构效应相关的残基,这些残基与影响正构结合的残基不同。已经报道了几种P2X配体门控离子通道和G蛋白偶联P2Y受体核苷酸的小分子变构调节剂。P2X受体的金属离子调节已得到广泛研究。嘌呤和嘧啶受体调节的变构方法对于开发作用具有事件和位点特异性的药物看来很有前景。